DK2599771T3 - Naphthalenderivat - Google Patents

Naphthalenderivat Download PDF

Info

Publication number
DK2599771T3
DK2599771T3 DK11812583.0T DK11812583T DK2599771T3 DK 2599771 T3 DK2599771 T3 DK 2599771T3 DK 11812583 T DK11812583 T DK 11812583T DK 2599771 T3 DK2599771 T3 DK 2599771T3
Authority
DK
Denmark
Prior art keywords
amino
substituted
naphthalene
sulfonic acid
ylazo
Prior art date
Application number
DK11812583.0T
Other languages
English (en)
Inventor
Akira Kakizuka
Seiji Hori
Toshiyuki Shudo
Tomohiro Fuchigami
Original Assignee
Daito Chemix Corp
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daito Chemix Corp, Univ Kyoto filed Critical Daito Chemix Corp
Application granted granted Critical
Publication of DK2599771T3 publication Critical patent/DK2599771T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/10—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/47—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having at least one of the sulfo groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/48—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)

Claims (17)

1. Forbindelse repræsenteret ved følgende formel (I) eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf, til anvendelse ved behandling af en valosinholdig protein (VCP)-medieret sygdom:
(i) hvor: R er phenyl, pyridyl, quinolinyl eller thiophenyl, som hver især kan have én eller flere substituenter Ra; hvert Ra er uafhængigt valgt blandt halogen; alkyl; substitueret alkyl; alkenyl; substitueret alkenyl; alkynyl; substitueret alkynyl; aryl; substitueret aryl; cycloalkyl; substitueret cycloalkyl; cycloalkenyl; substitueret cycloalkenyl; heteroaryl; substitueret heteroaryl; heterocyclyl; substitueret heterocyclyl; amino; substitueret amino repræsenteret ved -NR21R22, hvor R21 og R22 uafhængigt er valgt blandt hydrogen, R30 og -SO2-R30, eller R21 og R22 danner, sammen med det nitrogen, hvormed de er forbundet, heterocyclyl eller substitueret heterocyclyl, under forudsætning af at R21 og R22 ikke samtidigt er hydrogen; cyano; nitro; acyl valgt blandt H-C(O)-, R30-C(O)- og NR27R28-NR26-C(0)- hvor R26, R27 og R28 uafhængigt er valgt blandt hydrogen, R30, -C(0)0-R3° og -SO2-R30, eller R27 og R28 danner, sammen med det nitrogen, hvormed de er forbundet, heterocyclyl eller substitueret heterocyclyl; acylamino repræsenteret ved -NR20C(O)-R30, hvor R20 er hydrogen, alkyl eller substitueret alkyl; alkoxy; substitueret alkoxy; carboxyl; carboxylester repræsenteret ved -C(0)0-R3°; thioacyl valgt blandt H-C(S)- og R30-C(S)-; thiocyanat; thiol; alkylthio; substitueret alkylthio; substitueret sulfonyl repræsenteret ved -SO2-R30; aminosulfonyl repræsenteret ved -SC>2NR23R24, hvor R23 og R24 uafhængigt er valgt blandt hydrogen, R30, hydroxy, alkoxy, substitueret alkoxy, amino, hvor den ovenfor definerede substituerede amino og den ovenfor definerede acylamino, eller R23 og R24 danner, sammen med det nitrogen, hvormed de er forbundet, heterocyclyl eller substitueret heterocyclyl; og aminocarbonyl repræsenteret ved -C(0)NR23R24, hvor R23 og R24 er som defineret ovenfor; R30 er valgt blandt alkyl, substitueret alkyl, alkenyl, substitueret alkenyl, alkynyl, substitueret alkynyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, cycloalkenyl, substitueret cycloalkenyl, heteroaryl, substitueret heteroaryl, heterocyclyl, og substitueret heterocyclyl; det ovenfor substituerede alkyl, substitueret alkenyl, substitueret alkynyl og substitueret alkoxy er uafhængigt substitueret med én eller flere substituenter Rb; hvert Rb er uafhængigt valgt blandt alkoxy; substitueret alkoxy; den ovenfor definerede acyl; den ovenfor definerede acylamino; acyloxy repræsenteret ved -C(0)0-R3°; amino; den ovenfor definerede substituerede amino; den ovenfor definerede aminocarbonyl; aminothiocarbonyl repræsenteret ved -C(S)NR23R24, hvor R23 og R24 er som defineret ovenfor; aminocarbonylamino repræsenteret ved -NR20C(O)NR23R24, hvor R20, R23 og R24 er som defineret ovenfor; aminothiocarbonylamino repræsenteret ved -NR20C(S)NR23R24, hvor R20, R23 og R24 er som defineret ovenfor; aminocarbonyloxy repræsenteret ved -0-C(0)NR23R24, hvor R23 og R24 er som defineret ovenfor; aminosulfonyl repræsenteret ved -SC>2NR23R24, hvor R23 og R24 er som defineret ovenfor; aminosulfonyloxy repræsenteret ved -0-SC>2NR23R24, hvor R23 og R24 er som defineret ovenfor; aminosulfonylamino repræsenteret ved -NR20-SC>2NR23R24, hvor R20, R23 og R24 er som defineret ovenfor; amidino repræsenteret ved -C(=NR25)NR23R24, hvor R25 er valgt blandt hydrogen, R30, hydroxy, alkoxy, substitueret alkoxy, amino, den ovenfor definerede substituerede amino og den ovenfor definerede acylamino, og R23 og R24 er som defineret ovenfor; aryl; substitueret aryl; aryloxy; substitueret aryloxy; arylthio; substitueret arylthio; azid; carboxyl; den ovenfor definerede carboxylester; (carboxylester)amino repræsenteret ved -NR20-C(O)O-R30, hvor R20 er som defineret ovenfor; (carboxylester)oxy repræsenteret ved -0-C(0)0-R3°, hvor R30 er som defineret ovenfor; cyano; cyanat; cycloalkyl; substitueret cycloalkyl; cycloalkyloxy; substitueret cycloalkyloxy; cycloalkylthio; substitueret cycloalkylthio; cycloalkenyl; substitueret cycloalkenyl; cycloalkenyloxy; substitueret cycloalkenyloxy; cycloalkenylthio; substitueret cycloalkenylthio; guanidino; substitueret guanidino repræsenteret ved -NR29C(=NR29)N(R29)2, hvor hvert R29 uafhængigt er valgt blandt hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl, eller to R29'ere forbundet med det samme guanidinonitrogenatom, danner, sammen med det nitrogen, hvortil de er forbundet, heterocyclyl eller substitueret heterocyclyl, underforudsætning af at i det mindste ét R29 ikke er hydrogen; halogen; hydroxy; hydroxyamino; alkoxyamino; hydrazino; substitueret hydrazino repræsenteret ved -NR26NR27R28, hvor R26, R27 og R28 er som defineret ovenfor; heteroaryl; substitueret heteroaryl; heteroaryloxy; substitueret heteroaryloxy; heteroarylthio; substitueret heteroarylthio; heterocyclyl; substitueret heterocyclyl; heterocyclyloxy; substitueret heterocyclyloxy; heterocyclylthio; substitueret heterocyclylthio; nitro; spirocycloalkyliden; SO3H; den ovenfor definerede substituerede sulfonyl, -OSO2-R30, den ovenfor definerede thioacyl; thiocyanat; thiol; alkylthio; og substitueret alkylthio; idet det ovenfor substituerede aryl, substitueret cycloalkyl, substitueret cycloalkenyl, substitueret heteroaryl og substitueret heterocyclyl uafhængigt er substituerede med én eller flere substituenter Rc; hvert Rc er uafhængigt valgt blandt oxo, thion, alkyl, substitueret alkyl, alkenyl, substitueret alkenyl, alkynyl, substitueret alkynyl, alkoxy, substitueret alkoxy, den ovenfor definerede acyl, den ovenfor definerede acylamino, den ovenfor definerede acyloxy, amino, den ovenfor definerede substituerede amino, aminocarbonyl, den ovenfor definerede aminothiocarbonyl, den ovenfor definerede aminocarbonylamino, den ovenfor definerede aminothiocarbonylamino, den ovenfor definerede aminocarbonyloxy, den ovenfor definerede aminosulfonyl, den ovenfor definerede aminosulfonyloxy, den ovenfor definerede aminosulfonylamino, den ovenfor definerede amidino, aryl, substitueret aryl, aryloxy, substitueret aryloxy, arylthio, substitueret arylthio, azid, carboxyl, den ovenfor definerede carboxylester, den ovenfor definerede (carboxylester)amino, den ovenfor definerede (carboxylester)oxy, cyano, cyanat, cycloalkyl, substitueret cycloalkyl, cycloalkyloxy, substitueret cycloalkyloxy, cycloalkylthio, substitueret cycloalkylthio, cycloalkenyl, substitueret cycloalkenyl, cycloalkenyloxy, substitueret cycloalkenyloxy, cycloalkenylthio, substitueret cycloalkenylthio, guanidino, den ovenfor definerede substituerede guanidino, halogen, hydroxy, hydroxyamino, alkoxyamino, hydrazino, den ovenfor definerede substituerede hydrazino, heteroaryl, substitueret heteroaryl, heteroaryloxy, substitueret heteroaryloxy, heteroarylthio, substitueret heteroarylthio, heterocyclyl, substitueret heterocyclyl, heterocyclyloxy, substitueret heterocyclyloxy, heterocyclylthio, substitueret heterocyclylthio, nitro, SO3H, den ovenfor definerede substituerede sulfonyl, sulfonyloxy, thioacyl, thiocyanat, thiol, alkylthio, og substitueret alkylthio; og når Rb eller Rc har en yderligere substituent, er den yderligere substituent som defineret ovenfor, underforudsætning af at Rb og Rc ikke har mere end tre substituenter.
2. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf til anvendelse ifølge krav 1, hvor Ra er fraværende eller hvert Ra uafhængigt er valgt blandt halogen, alkyl, substitueret alkyl, alkenyl, substitueret alkenyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl, substitueret heterocyclyl, cyano, nitro, acyl, acylamino, alkoxy, substitueret alkoxy, carboxyl, carboxylester, alkylthio, substitueret alkylthio, og aminocarbonyl, hvori den substituerede alkyl, substitueret alkenyl, substitueret aryl, substitueret heteroaryl, substitueret heterocyclyl, substitueret alkoxy og substitueret alkylthio uafhængigt er substituerede med én eller flere substituenter Rb eller Rc som defineret i krav 1.
3. Forbindelse til anvendelse ifølge krav 1 eller krav 2, som er en forbindelse repræsenteret ved følgende formel (II) eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf:
(i i) hvor m er et heltal fra 0 til 4.
4. Forbindelse til anvendelse ifølge krav 1 eller krav 2, som er en forbindelse repræsenteret ved følgende formel (III) eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf
(i i i) hvor n er et heltal fra 0 til 5.
5. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf til anvendelse ifølge ethvert af de foregående krav, hvor hvert Ra er uafhængigt valgt blandt alkenyl, substitueret alkenyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, cyano, carboxylester, alkylthio, substitueret alkylthio og aminocarbonyl, hvor den substituerede alkenyl, substitueret aryl, substitueret heteroaryl og substitueret alkylthio er substitueret med én eller flere substituenter Rb eller Rc som defineret i krav 1.
6. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf til anvendelse ifølge ethvert af de foregående krav, hvor den VCP-medierede sygdom er IBMPFD, en neurodegenerativ sygdom, en muskelsygdom, en knoglesygdom, en inflammatorisk sygdom, cystisk fibrose, en autoimmunsygdom, en viral infektion, en tumorsygdom, dyslipidæmi, hypertension, godartet prostatahyperplasi, kronisk obstruktiv pulmonær sygdom, hyppig vandladning, urininkontinens, irritabel tarmsyndrom, en allergisk sygdom, mavesår, tolvfingertarmssår, depression, angst, skizofreni, migræne, smerte eller opkast.
7. Forbindelse repræsenteret ved følgende formel (II) eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf:
(II) hvor: hvert Ra er uafhængigt valgt blandt halogen; alkyl eventuelt substitueret med 1,2 eller 3 halogensubstituenter; alkenyl eventuelt substitueret med 1,2 eller 3 substituenter valgt blandt aryl og cyano; aryl eventuelt substitueret med 1, 2 eller 3 substituenter valgt blandt halogen, alkyl, heterocyclyl, aryl, heteroaryl, acyl, cyano, alkoxy, aryloxy og hydroxyl; heteroaryl eventuelt substitueret med 1,2 eller 3 substituenter valgt blandt oxo og alkoxy; heterocyclyl; acyl; og alkoxy eventuelt substitueret med 1, 2 eller 3 substituenter valgt blandt halogen, heteroaryl, heterocyclyl og alkoxy; og m er et heltal fra 0 til 4.
8. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf ifølge krav 7, hvor hvert Ra uafhængigt er aryl eventuelt substitueret med 1,2 eller 3 substituenter valgt blandt halogen, alkyl, heterocyclyl, aryl, heteroaryl, acyl, cyano, alkoxy, aryloxy og hydroxy.
9. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf ifølge krav 7, hvor hvert Ra uafhængigt er heteroaryl eventuelt substitueret med 1, 2 eller 3 substituenter valgt blandt oxo og alkoxy.
10. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf ifølge ethvert af kravene 7 til 9, hvor m er 0, 1 eller 2.
11. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf ifølge krav 7, som er en forbindelse valgt blandt følgende forbindelser eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf: 4-amino-3-(pyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-methoxypyridin-3-ylazo)naphthalen-1-sulfonsyre; 3- (2-pyridinomethoxy-5-pyridinoazo)-4-amino-1-naphthalensulfonsyre; 4- amino-3-[6-(tetrahydrofuran-2-ylmethoxy)pyridin-3-ylazo]-1-naphthalensulfonsyre; 4-amino-3-[6-(2,2,2-trifluorethoxy)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-methoxyethoxy)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-(6-phenylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-p-tolylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-m-tolylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-o-tolylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-biphenyl-2-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-ethoxypyridin-3-ylazo)naphthalen-1-sulfonsyre; 3-[6-(2-acetylphenyl)pyridin-3-ylazo]-4-aminonaphthalen-1-sulfonsyre; 3-[6-(3-acetylphenyl)pyridin-3-ylazo]-4-aminonaphthalen-1-sulfonsyre; 3- [6-(4-acetylphenyl)pyridin-3-ylazo]-4-aminonaphthalensulfonsyre; 4- amino-3-(6-thiophen-2-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-thiophen-3-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-[6-(2,4-dichlorphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-chlorphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(3-chlorphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-chlorphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-methoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-methoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-isopropoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-isopropoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-phenoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-(6-styrylpyridin-3-ylazo)naphthalensulfonsyre; 4-amino-3-(6-dibenzothiophen-4-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-[6-(3-methoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2,3-dimethylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2,5-dimethylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(3,5-dimethylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-(6-oxazol-2-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-naphthalen-1-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-dibenzofuran-4-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; methyl 4-{4-[5-(1-amino-4-sulfonaphthalen-2-ylazo)pyridin-2-yl]phenyl}-4-oxobutyrat; 4-amino-3-(6-benzo[b]thiophen-3-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-biphenyl-3-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-[6-(3-cyanophenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-cyanophenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-benzoylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-propoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-fluor-2-methylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-(2-phenylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-([2,3']bipyridinyl-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-([2,3']bipyridinyl-5-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-methyl-[2,3']bipyridinyl-5-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-([3,2';6',3"]terpyridin-3'-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-[6-(5-fluor-2-propoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-fluor-6-propoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-fluor-2-propoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(5-fluor-2-methylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-fluor-5-methylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-butoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-hexyloxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-butylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-hydroxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-isobutoxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(5-chlor-2-hydroxyphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-methylbiphenyl-2-yl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-(6-thianthren-1-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-fluor-2-methylphenyl)-5-methylpyridin-3-ylazo]naphthalen-1- sulfonsyre; 4-amino-3-(6-quinolin-8-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-dibenzothiophen-4-yl-5-methylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-biphenyl-2-yl-5-methylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-methoxy-5-phenylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(6-chlor-5-phenylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(5,6-diphenylpyridin-3-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-[6-(2,6-dimethylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(3-formyl-2-isopropoxy-5-methylphenyl)pyridin-3-ylazo]naphthalen-1- sulfonsyre; 4-amino-3-[6-(3-formyl-2-butoxy-5-methylphenyl)pyridin-3-ylazo]naphthalen-1- sulfonsyre; 4-amino-3-[6-(2-butoxy-3-ethoxy-5-formylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; og 4-amino-3-[6-(2-ethoxy-3-formyl-5-methylphenyl)pyridin-3-ylazo]naphthalen-1- sulfonsyre.
12. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf ifølge krav 11, som er 4-amino-3-(6-phenylpyridin-3-ylazo)naphthalen-1 -sulfonsyre eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf.
13. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf ifølge krav 11, som er 4-amino-3-(6-biphenyl-2-ylpyridin-3-ylazo)naphthalen-1 -sulfonsyre eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf.
14. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf ifølge krav 11, som er 4-amino-3-[6-(4-fluor-2-methylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf.
15. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf ifølge krav 11, som er 4-amino-3-[6-(3-formyl-2-butoxy-5-methylphenyl)pyridin-3-ylazo]-naphthalen-1 -sulfonsyre eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf.
16. Forbindelse eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf ifølge krav 11, som er 4-amino-3-(6-dibenzothiophen-4-ylpyridin-3-ylazo)naphthalen-1-sulfonsyre eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf.
17. Forbindelse valgt blandt følgende forbindelser eller et oxid, et farmaceutisk acceptabelt salt eller solvat deraf: 4-amino-3-[6-(3-morpholin-4-ylmethylphenyl)pyridin-3-ylazo]naphthalen-1 -sulfonsyre; 4-amino-3-[6-(2-trifluormethylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(4-trifluormethylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(3-trifluormethylphenyl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(3,5-bistrifluormethylphenyl)pyridin-3-ylazo]naphthalensulfonsyre; 4-amino-3-{6-[2-(6-hydroxyhexyloxy)phenyl]pyridin-3-ylazo}naphthalen-1-sulfonsyre; 4-{2-[5-(1-amino-4-sulfonaphthalen-2-ylazo)pyridin-2-yl]phenoxy}smørsyre; 4-amino-3-{6-[2-(3-hydroxypropoxy)phenyl]pyridin-3-ylazo}naphthalen-1-sulfonsyre; 4-amino-3-{6-[2-(3-tert-butoxycarbonylaminopropoxy)phenyl]pyridin-3-ylazo}- naphthalen-1 -sulfonsyre; 4-amino-3-[6-(2-{3-[(2-chlorpyridin-3-carbonyl)amino]propoxy}phenyl)pyridin-3-ylazo]-naphthalen-1 -sulfonsyre; 4-amino-3-[6-(4'-chlor-4-methylbiphenyl-2-yl)pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-[6-(5,5-dioxo-5H-5A6-dibenzothiophen-4-yl)pyridin-3-ylazo]naphthalen-1- sulfonsyre; 4-amino-3-[6-(4,3', 5'-trimethylbiphenyl-2-yl)pyridin-3-ylazo]naphthalen-1 -sulfonsyre; 4-amino-3-[6-(3'-chlor-4-methylbiphenyl-2-yl)pyridin-3-ylazo]naphthalen-1 -sulfonsyre; 4-amino-3-[6-(2-{3-[(2-chlorpyridin-4-carbonyl)amino]propoxy}phenyl)pyridin-3-ylazo]-naphthalen-1 -sulfonsyre; 4-amino-3-(6-{2-[3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)propoxy]phenyl}pyridin-3-ylazo)-naphthalen-1 -sulfonsyre; 4-amino-3-{6-[3-(pyridin-3-ylmethoxy)dibenzothiophen-4-yl]pyridin-3-ylazo}naphthalen-1-sulfonsyre; 4-amino-3-[6-(3-{3-[(2-chlorpyridin-3-carbonyl)amino]propoxy}dibenzothiophen-4-yl)-pyridin-3-ylazo]naphthalen-1-sulfonsyre; 4-amino-3-{6-[3-(3-hydroxypropoxy)dibenzothiophen-4-yl]pyridin-3-ylazo}naphthalen-1-sulfonsyre; 4-amino-3-[6-(2-methylquinolin-8-yl)pyridin-3-ylazo]naphthalen-1 -sulfonsyre; 4-amino-3-(2-fluorphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-[4-[(2-thienylcarbonyl)amino]phenylazo]-1-naphthalensulfonsyre; 4-amino-3-(3-fluorphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-fluorphenylazo)naphthalen-1 -sulfonsyre; 4-amino-3-(2-cyanophenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(3-cyanophenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-cyanophenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(2,4-dichlorphenylazo)naphthalen-1 -sulfonsyre; 4-amino-3-(3,4-dichlorphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(2,4-dibromphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(2,4,6-tribromphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(2,4-difluorphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(2-brom-4-chlorphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-chlor-2-cyanophenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(2-chlor-4-fluorphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-methyl-2-nitrophenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-pyridin-3-ylphenylazo)-1-naphthalensulfonsyre; 2-{4-[4-(1-amino-4-sulfonaphthalen-2-ylazo)benzoylamino]benzyl}malonsyre; 4-amino-3-(4'-methylbiphenyl-4-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(3'-methylbiphenyl-4-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-isoquinolin-1-ylphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(2,6-dibrom-4-pyridin-3-ylphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-phenylcarbamoylphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(3-benzoylphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-benzoylphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-[4-(pyridin-4-ylmethoxy)phenylazo]naphthalen-1-sulfonsyre; 4-amino-3-(2-methylsulfanylphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-(4-methylsulfanylphenylazo)naphthalen-1-sulfonsyre; 4-amino-3-[4-(pyridin-3-ylmethoxy)phenylazo]naphthalen-1-sulfonsyre; 4-amino-3-[4-(pyridin-2-ylmethoxy)phenylazo]naphthalen-1-sulfonsyre; 4-amino-3-[3-(pyridin-2-ylmethoxy)phenylazo]naphthalen-1-sulfonsyre; 4-amino-3-[3-(pyridin-3-ylmethoxy)phenylazo]naphthalen-1-sulfonsyre; 4-amino-3-[3-(pyridin-4-ylmethoxy)phenylazo]naphthalen-1-sulfonsyre; 4-amino-3-[2-(pyridin-2-ylmethoxy)phenylazo]naphthalen-1-sulfonsyre; 4-amino-3-[2-(pyridin-4-ylmethoxy)phenylazo]naphthalen-1-sulfonsyre; 4-amino-3-[2-(pyridin-3-ylmethoxy)phenylazo]naphthalen-1-sulfonsyre; 4-amino-3-[4-(2-cyano-2-phenylvinyl)phenylazo]naphthalen-1-sulfonsyre; 4-amino-3-(2,4'-difluor-2'-methyl-diphenyl-4-ylazo)naphthalen-1-sulfonsyre; 4-amino-3-(quinolin-3-ylazo)naphthalen-1-sulfonsyre; methyl 3-(1-amino-4-sulfonaphthalen-2-ylazo)thiophen-2-carboxylat; og 4-amino-3-(quinolin-6-ylazo)naphthalen-1-sulfonsyre.
DK11812583.0T 2010-07-30 2011-07-28 Naphthalenderivat DK2599771T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010172467 2010-07-30
PCT/JP2011/067320 WO2012014994A1 (ja) 2010-07-30 2011-07-28 ナフタレン誘導体

Publications (1)

Publication Number Publication Date
DK2599771T3 true DK2599771T3 (da) 2016-10-24

Family

ID=45530194

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11812583.0T DK2599771T3 (da) 2010-07-30 2011-07-28 Naphthalenderivat

Country Status (7)

Country Link
US (1) US9573887B2 (da)
EP (1) EP2599771B1 (da)
JP (1) JP5828201B2 (da)
DK (1) DK2599771T3 (da)
ES (1) ES2594556T3 (da)
PT (1) PT2599771T (da)
WO (1) WO2012014994A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822840B2 (ja) * 2010-09-30 2015-11-24 ダイトーケミックス株式会社 眼疾患処置薬
DK2959903T3 (da) * 2013-02-20 2019-01-21 Univ Kyoto Medicin til behandling af øjensygdom
PT3042658T (pt) 2013-09-04 2019-05-13 Univ Kyoto Composição medicinal que melhora a resistência à leptina
WO2015129809A1 (ja) * 2014-02-28 2015-09-03 国立大学法人京都大学 虚血性眼疾患の処置用の医薬組成物
CN104447433A (zh) * 2014-11-11 2015-03-25 常州大学 一种合成3,5-二溴对甲苯磺酰氯的方法
FR3041358B1 (fr) * 2015-09-21 2017-11-24 Commissariat Energie Atomique Electrolyte pour generateur electrochimique
WO2017070320A1 (en) 2015-10-21 2017-04-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Phenyl indole allosteric inhibitors of p97 atpase
CN106892865A (zh) * 2015-12-19 2017-06-27 西安瑞联新材料股份有限公司 一种2,4-二氯-6-对甲苯基喹啉的合成方法
CN107961235B (zh) * 2017-12-27 2019-09-24 湖北工业大学 芳香酯化合物wy124用于制备抗adv-7病毒的药物
ES2925638T3 (es) * 2017-12-27 2022-10-19 Univ Kyoto Composición para la protección de la córnea
US11023185B2 (en) 2018-01-08 2021-06-01 Hewlett-Packard Development Company, L.P. Collective awareness of supplies
US12011438B2 (en) 2018-04-16 2024-06-18 Kyoto University Composition for protecting cardiomyocyte
US12522587B2 (en) 2018-05-04 2026-01-13 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
JP7101982B2 (ja) * 2018-07-31 2022-07-19 国立大学法人京都大学 脳梗塞の処置用の医薬組成物
CN114599370A (zh) * 2019-10-24 2022-06-07 国立大学法人京都大学 用于保护软骨的药物组合物
EP4055008A1 (en) 2019-11-06 2022-09-14 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
ES2972239T3 (es) * 2020-01-15 2024-06-11 Huntsman Textile Effects Switzerland Gmbh Pigmentos azo dispersos, un proceso para su preparación, y su uso
WO2022122668A1 (en) 2020-12-07 2022-06-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Combined inhibition of amino acid transporters for inhibiting human plasmacytoid dendritic cell activity during autoimmunity
EP4008330A1 (en) * 2020-12-07 2022-06-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Combined inhibition of amino acid transporters for inhibiting human plasmacytoid dendritic cell activity during autoimmunity
CN112961119A (zh) * 2021-01-21 2021-06-15 廊坊师范学院 一种非布司他杂质的制备方法
JP7705649B2 (ja) 2021-04-28 2025-07-10 国立大学法人京都大学 皮膚組織の異常を改善するための組成物
WO2023120704A1 (ja) 2021-12-24 2023-06-29 国立大学法人京都大学 心機能を改善するための組成物
KR20240146680A (ko) * 2022-02-09 2024-10-08 메르크 파텐트 게엠베하 유기 전계 발광 디바이스용 재료
KR20250093323A (ko) 2022-10-27 2025-06-24 가부시키가이샤 교토 소야쿠 겐큐쇼 나프탈렌 유도체의 결정
EP4628084A1 (en) 2022-11-28 2025-10-08 Kyoto University Naphthalene-derivative-based therapeutic drug for ophthalmological disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2865916A (en) * 1958-12-23 Triazole brighteners
JPS58174463A (ja) * 1982-04-08 1983-10-13 Canon Inc 記録液
DE3417237A1 (de) * 1984-05-10 1985-11-14 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von nickel-komplexfarbstoffen
CN86105522B (zh) * 1986-07-29 1988-03-23 大连工学院 一类含氰基的水溶性染料合成方法
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
DE10053796A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Verwendung von Naphthalinsulfonamiden
JP2004075921A (ja) * 2002-08-21 2004-03-11 Konica Minolta Holdings Inc インクジェット記録液
WO2006025304A1 (ja) * 2004-08-30 2006-03-09 Kyushu University, National University Corporation 動脈硬化検知用ｍｒｉ造影剤
CN1322064C (zh) * 2005-10-18 2007-06-20 朱海根 一种高匀染性的复合活性黑染料
CN101289579B (zh) * 2007-04-16 2011-03-30 明德国际仓储贸易(上海)有限公司 黑色染料组成物及黑色墨水组成物
CN101633796B (zh) * 2009-08-17 2013-01-09 浙江劲光化工有限公司 一种复合活性黑染料

Also Published As

Publication number Publication date
US20130184241A1 (en) 2013-07-18
JPWO2012014994A1 (ja) 2013-09-12
EP2599771B1 (en) 2016-09-14
JP5828201B2 (ja) 2015-12-02
ES2594556T3 (es) 2016-12-21
WO2012014994A1 (ja) 2012-02-02
US9573887B2 (en) 2017-02-21
EP2599771A4 (en) 2014-03-19
PT2599771T (pt) 2016-12-14
EP2599771A1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
DK2599771T3 (da) Naphthalenderivat
US6635641B2 (en) Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
US8598355B2 (en) Amide compound
KR101887599B1 (ko) 칼슘 방출-활성화 칼슘 통로의 조정제로서의 피라졸 유도체
US11273153B2 (en) MAPK inhibitors
US9624215B2 (en) Amine derivative or salt thereof
KR20100064381A (ko) 아미드 화합물
OA11980A (en) Indazole compounds and pharmaceutical compositionsfor inhibiting protein kinases, and methods for t heir use.
CA2541299A1 (en) Amide compounds as ion channel ligands and uses thereof
CN102791690A (zh) 作为抗癌药的二取代吡啶衍生物
JP2016540802A (ja) Ｗｎｔ経路のモジュレーターとしてのマレイミド誘導体
KR20200040841A (ko) 벤젠 축합 헤테로환 유도체 및 이를 포함하는 약학 조성물
TW201406736A (zh) 新穎的醯胺衍生物或其鹽
JP6937524B2 (ja) アミド化合物およびその使用
CA2637631A1 (en) Pyrimidine compounds and uses thereof
CA2933026A1 (en) Novel pyridine pyrazinones as brd4 inhibitors
US20130123500A1 (en) Ethinyl-pyrazole derivative
JP2018531266A (ja) ピリドン誘導体およびキナーゼ阻害剤としてのその使用
JP2018531266A6 (ja) ピリドン誘導体およびキナーゼ阻害剤としてのその使用
AU2006231008A1 (en) Acyl hydrazides as kinase inhibitors, in particular for SGK
AU2016366443A1 (en) Aminoazole derivative